Inspection Record

Glopec International Inc. — Health Canada Inspection Findings

Health CanadaInspected 2022-06-21 8 findingsLabeling and packagingComplaint and recall handlingStability and storageEquipment and facilityDeviation, CAPA, and investigationOther quality system

View the regulator's official source The source document is always the basis for judgement.

Findings

1Labeling and packaging

The importer did not ensure that the foreign sites use to fabricate, package/label, or test drug products met the requirements described in Guidance on Evidence to Demonstrate Drug GMP Compliance of Foreign Sites (GUI-0080).

3Stability and storage

The guidelines and/or procedures were inadequate in ensuring storage and/or transportation conditions would maintain the quality and safe distribution of the drug.

5Equipment and facility

The training of personnel in good manufacturing practices and/or the maintenance of records was inadequate.

6Equipment and facility

The availability, content and/or maintenance of the quality agreements between the supplier, fabricator, tester, packager, labeller, distributor, importer, and/or wholesaler was inadequate.

7Deviation, CAPA, and investigation

Investigations into deviations, reports, and/or follow-up actions were inadequate.

8Other quality system

The assessment to release finished products was inadequate.

About this record

Extracted automatically from the document of the Health Canada inspection on 2022-06-21. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Glopec International Inc. company profile — full historyAll Health Canada findings Health Canada documents, 2022 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.